About us



Since September 2015, Mr. Schubert is a Consultant in the fields of Health, Research and the Biopharmaceutical industry. Mr. Schubert brings more than 35 years of national and international experience in pharmacy, healthcare and biopharmaceutical industry. In addition to executive/senior management experience, Mr. Schubert is a researcher in Health economics and held the position of Worldwide Vice-President of the Global Health Outcomes department at Glaxo Wellcome/Glaxo Smith Kline headquarters offices in London, UK from 1995 to 2001. He holds degrees in pharmacy, health administration and public health and is a fellow of several Canadian and American professional associations. In July 2015, he was named Member of the Order of Canada. Mr. Schubert has also extensive committee and Board experience having chaired several National and International Organizations. Between 2014 and 2015, he was member of Aligo's Board of Directors while he was General Manager and Chief Administration Officer of the Research Institute of the MUHC.


With degrees in Administration from the University of Quebec à Rimouski, in Executive Programs from CIREM-HEC, and in Advanced Management from McGill, Laurent Bellavance has over 25 years of management experience in marketing, business development, strategic planning, and innovation technology. From 1990 to 1997, he worked for Groupe Bellavance as administrator and head of development where he founded Bellco, a startup in the field of computer graphics. In 1997 his career turned toward telecommunications with QuébecTel. Here he successively held the positions of Product Analyst, Marketing Director, and Strategic Planning Director and was heavily involved in provincial business development and the merger of QuébecTel with TELUS. In 2006 he focused his efforts on economic development by joining the Economic Development Corporation of Rimouski and then Technopole Maritime du Québec (TMQ), where he set up a national and international development plan that will position TMQ and Quebec among the leaders of Marine Science and Technology innovation and research. Laurent has been Managing Director of Nosotech since February 2014. Nosotech develops management software for the control and prevention of infections and the monitoring of antibiotic use in hospitals and has initiated an international expansion plan for its products.


Prof. Sylvain G. Cloutier is Dean of Research at the École de technologie supérieure (ÉTS). He received an undergraduate degree in Engineering Physics and a master’s degree in Physics from the Université Laval in 2001 and 2003. In 2006, he received the Outstanding PhD Thesis Award from the Division of Engineering at Brown University where he studied the optoelectronic properties of nano-engineered materials. He then became an assistant professor of Electrical and Computer Engineering at the University of Delaware. In 2008, he received the DARPA Young Faculty Award for his work on the use of nano-engineered materials for lasers. In 2011, he joined the Electrical Engineering Department at the ÉTS, where leads the Canada Research Chair on Hybrid Optoelectronic Materials and Devices. In 2014, he was elected to the College of New Scholars, Artists and Scientists of the Royal Society of Canada. He published more than 70 articles cited over 1100 times.


Pierre-Richard Gaudreault received his doctorate in plant biochemistry from Carleton University in Ottawa. He has over 35 years of experience in research (University of Oklahoma, McGill University, National Research Council Canada) and research administration (university-industry partnership programs in The Natural Sciences and Engineering Research Council of Canada, Université de Sherbrooke). Pierre-Richard is Executive Director of Service d’appui à la recherche, à l’innovation et à la création (SARIC) and Associate Vice-President in Research, Innovation, and Entrepreneurship at the Université de Sherbrooke.


François is a Chartered Professional Accountant (CPA, CA) with over thirty years of experience in mergers and acquisitions, international tax planning, and venture capital. Since 2007 François has been a Partner and Chief Financial Officer of iNovia Capital. Before joining the ranks of iNovia, he was the Investment Director of the Fonds de solidarité FTQ, a $9 billion Montreal-based labor-sponsored fund. He was responsible for all of the venture capital investments for FTQ. François previously held senior management positions at Steinberg, Teleglobe, and BCE, where he participated in numerous merger and acquisition transactions. Francis began his career with Coopers & Lybrand (now PricewaterhouseCoopers).


Guy Lemieux is a business coach specializing in helping CEOs and management teams in the high tech industry, including telecommunications, electronics, and information technology. He began his career on the technical side in transmission, switching, and computer communications with Bell Canada. He then held positions in marketing and IT before assuming the leadership of national sales at Northern Telecom. He took on the role of President of Bell Mobility Radio, which provides two-way voice and wireless data services to emergency agencies in Canada. His career continued as CEO of Nertec Design (manufacturer of remote reading meters) and in LTRIM Technologies (manufacturer of precision analog semiconductors). He has served on the Board of Directors of many companies: InterTrade (e-commerce), Vizimax Inc. (products that optimize the generation, movement, and consumption of energy), Valeo (university technology development and financing), iMetrik Global (a network provider of M2M solutions), Usito (electronic dictionary), and NoviFlow (advanced systems for switching high-speed data). Guy holds a Degree in Administrative Sciences with a concentration in finance from Université Laval and occasionally advises technology investment funds.


Bruce Mazer is a professor of pediatrics and the newly appointed Interim Executive Director and Chief Scientific Officer of the Research Institute of the McGill University Health Centre (RI-MUHC). He also is Head of Child Health Research at the Montreal Children’s Hospital of the McGill University Health Centre (MCH-MUHC). Dr. Mazer obtained his MD and trained in pediatrics at McGill University, then completed a fellowship in allergy and immunology at the National Jewish Health Center in Denver, CO. He returned to the Montreal Children’s Hospital (MCH) in 1991 and since then has remained a member of the Division of Allergy and Immunology, and of the research institute at the MCH that later merged with the RI-MUHC. He has been director of the largest pediatric allergy and immunology academic practice in Canada at the MUHC and a research director at the Meakins Christie Laboratories, McGill’s pulmonary research institute. Most recently, he was the Head of the Divisions of Allergy, Immunology and Dermatology at the MCH-MUHC. Dr. Mazer has been very active in chairing RI-MUHC committees, including those responsible for the equipment competition, bridge funding, and evaluation of grant reviews, and he chaired the Research Council from 2008-2014. His research interests include understanding the role of B-cells, plasma cells and Intravenous Immunoglobulin in tolerance and immune regulation, understanding defects in B-cell memory and antibody disorders, and developing novel biomarkers for oral tolerance and food desensitization. He has been funded by the CIHR, the FRQS, NSERC, ALLERGEN-NCE, and Immunodeficiency Canada. He was awarded a William Dawson Scholarship at McGill University and was a chercheur national of the Fonds de recherche du Québec – Santé (FRQS).


Dr Catherine Mounier obtained her B.Sc. in Biochemistry (1987) and her M.Sc. in Molecular Chemistry (1988) from Rennes University (France). She then obtained her Ph.D. in Cellular and Molecular Biology (1994) at the National Superior Agronomic school in Rennes (France). Dr Mounier then continued her investigations through a first postdoctoral training at the Biochemistry Department of Iowa University (USA) where she studied the transcriptional regulation of the avian malic enzyme gene. During a second postdoctoral training at McGill University (Montreal, Canada), she participated in the identification of new hepatic cell signaling pathways triggered by insulin and EGF ligands. Dr Mounier is a professor at the Biological Sciences Department of Université du Québec à Montréal (UQAM) since 2003 and was promoted to full professor in 2012. She acted as Assistant Director of this department from 2007 to 2012, then as Director from 2012 to 2015. As of July 2015, she was appointed Vice-President Research at UQAM. Her research projects focus on lipid metabolism and insulin sensitivity, with a particular emphasis on nutritional and hormonal regulation of genes involved in hepatic lipogenesis. Hepatic steatosis (accumulation of exces fat in liver cells) in hence a focal point of research in her laboratory.